What is the clinical evidence from this study?

Study design: Review. Population: Pulmonary arterial hypertension.

What question did this study set out to answer?

To explore the complex mechanisms contributing to pulmonary arterial hypertension and recent therapeutic advancements.

June 19, 2026Chinese Medical JournalOpen Access

Pulmonary arterial hypertension from a translational perspective: Bridging pathophysiology and treatment

View Full Paper

Ask AI

Bookmark

Key result

Translational breakthroughs in PAH yield novel therapies targeting BMP/TGF-β, inflammation, and metabolic remodeling.

Population

Patients with Pulmonary arterial hypertension (PAH)

Design

Review

Authors

TYTaeil YangGachon University WCWook-Jin Chung

Discussion

Member takes

Implication

Encourages trial enrollment in PAH; leaves open whether novel pathway-targeted therapies will alter outcomes.

Key Points

To explore the complex mechanisms contributing to pulmonary arterial hypertension and recent therapeutic advancements.
Discussed the pathophysiology of pulmonary arterial hypertension including vascular remodeling and genetic factors.
Reviewed novel treatment strategies targeting specific molecular pathways.
Summarized ongoing clinical trials and multi-omics initiatives for better understanding and treatment of PAH.
Identified multiple pathways contributing to PAH, including endothelial dysfunction and immune activation.
Highlighted novel therapies like sotatercept and seralutinib that target underlying mechanisms of the disease.
Noted importance of precision medicine approaches informed by large-scale phenotyping initiatives.

Structured PICO

Population

Patients with Pulmonary arterial hypertension (PAH)

This review highlights the evolving understanding of PAH from pure vasoconstriction to a complex vasculopathy, emphasizing the emergence of novel targeted therapies and precision medicine approaches.

Cite This Study

Yang et al. (2026) conducted a review in Pulmonary arterial hypertension. Recent translational breakthroughs in pulmonary arterial hypertension have yielded novel therapeutic strategies targeting the BMP/TGF-β axis, inflammatory pathways, and metabolic remodeling.

synapsesocial.com/papers/6a35982fdd3be7785e70ed26 https://doi.org/10.1097/cm9.0000000000004137

View Full Paper

Ask AI

Bookmark